Edgewise Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | 1,059 | -534 | -525 | |
EBITDA | -47,095 | -39,830 | -37,627 | -34,280 |
EBIT | -45,434 | -40,432 | -38,161 | -34,805 |
Net Income | -39,662 | -34,129 | -31,497 | -28,525 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -27,231 | -27,894 | -26,320 | -28,895 |
Cash | 41,666 | 44,806 | 43,485 | 30,264 |
Basic Shares | 92,414 | 93,813 | 93,515 | 87,567 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1,732 | -538 | -272 | |
EBITDA | -158,832 | -112,806 | -21,541 | -42,943 |
EBIT | -114,538 | -22,079 | -43,215 | |
Net Income | -133,813 | -100,163 | -15,397 | -42,139 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 6,427 | -89,350 | ||
Free Cash Flow | -110,340 | -97,693 | -58,181 | -34,175 |
Cash | 41,666 | 86,097 | 351,947 | 280,789 |
Basic Shares | 92,414 | 63,723 | 53,593 | 49,500 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.42 |
2024-09-30 | -$0.36 |
2024-06-30 | -$0.34 |
2024-03-31 | -$0.33 |
